Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 7/20 | 0.47 |
| ▸ | ACACA | Q13085 | 7/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | RHOA | P61586 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600251 | 0.90 | RHOA (0.57) | NPC1RAB9AALDH1A1PKMACACB | |
| SCHEMBL599177 | 0.82 | KDM4E (0.59) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL599098 | 0.81 | L3MBTL3 (0.46) | ACACBACACAHRH3RHOAL3MBTL3 | |
| SCHEMBL600062 | 0.80 | L3MBTL3 (0.44) | ACACBACACAHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL600472 | 0.79 | ABL1 (0.53) | HRH3RHOAL3MBTL3L3MBTL1 | |
| SCHEMBL600180 | 0.79 | MAPK14 (0.52) | NPC1RAB9AHRH3L3MBTL3L3MBTL1 | |
| SCHEMBL599543 | 0.78 | HRH3 (0.55) | ALDH1A1HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL7893397 | 0.78 | L3MBTL3 (0.55) | ALDH1A1HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL599523 | 0.77 | ALDH1A1 (0.59) | ALDH1A1HRH3SMN1; SMN2L3MBTL3L3MBTL1 | |
| SCHEMBL600534 | 0.77 | MKNK1 (0.51) | HPGDACACBACACAHRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | claimed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | claimed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | claimed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-2391617-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH3, HRH2, HRH1 | NPC1 2650/4885RAB9A 590/4885ALDH1A1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.